

INTERIM REPORT

Q4 2021

THE POWER
OF PRECISION.
FOR EVERY
ONCOLOGIST.
TODAY.

The logo for 2curex, featuring a stylized '2' followed by the word 'curex' in a lowercase, sans-serif font.

HIGHLIGHTS AND KEY FIGURES

ESTABLISHING A SOLID BASE IN EUROPE

As a company, 2cureX experienced a continuous progress in 2021, and we can proudly say that we reached the objectives we have set for the year.

In Q4 2021 we obtained three new distribution agreements covering four new countries, added one new test (IndiTreat® Start) to our portfolio, enrolled the first hospital for our IGNITE program, and received the first commercial order in the history of 2cureX. With this we have further expanded our commercial reach, and this unprecedented series of events lay the ground for an ambitious 2022, where we expect to see IndiTreat® tests being routinely used to personalize cancer treatment across Europe.

We have grown the IndiTreat® distribution network from six countries in August 2021 to fourteen countries at the beginning of 2022, and for the full year of 2022 we expect to continue the expansion.

After we signed an agreement with Werfen (Spain) in September, then Labormed (Slovenia), Omnigen (Turkey) and Diamedica (Latvia and Lithuania) followed in Q4 2021.

Furthermore, in the first week of January 2022 two new agreements with the companies Perlan (Poland) and Promedica (Czech and Slovakia) completed the current map.

All new distributors are In Vitro Diagnostics (IVD) companies well established in their markets, with a portfolio of products that is complementary to IndiTreat®, and extensive coverage of our target customers through sales and customer support networks.

In December 2021 we launched the new IndiTreat® mCRC Start. IndiTreat® mCRC Start is a test to help oncologists decide which of the available chemotherapy combinations – known as FOLFOX, FOLFIRI and FOLFOXIRI – is better suited for a specific patient as first line treatment.

FINANCIAL HIGHLIGHTS


The financial development continues to be in line with our expectations, and with a cash position of SEK 72.9 million at the end of Q4 2021, our capital resources support the current activities and growth plans.

(KSEK)	Q4 2021 1/10-31/12	Q4 2020 1/10-31/12	Q1-Q4 2021 1/1-31/12	Q1-Q4 2020 1/1-31/12
Net sales	0	0	0	0
Other operating income	2 541	5 212	7 391	15 391
Profit before tax	-6 476	-2 818	-21 679	-8 591
Earnings per share (SEK)*	-0,31	-0,15	-1,10	-0,54
Equity ratio**	93%	93%	93%	93%
Cash and bank	72 942	58 577	72 942	58 577
Average number of shares	17 475 716	14 852 683	16 418 767	13 604 775
No. of shares by the end of the period	17 475 716	14 856 600	17 475 716	14 856 600

*Earnings per share: Profit for the period divided by the average number of shares.

**Equity ratio: Shareholder's equity divided by total capital.

SIGNIFICANT EVENTS IN Q4



FOR MORE INFORMATION PLEASE CONTACT:

Fernando Andreu, CEO
 Mail: fa@2curex.com
 Mobile: +45 2279 5399

Ole Thastrup, CSO
 Mail: ot@2curex.com
 Mobile: +45 2211 5399

www.2curex.com



YEAR-END SPRINT SECURING A SOLID BASE IN EUROPE

2021 was a year of continuous progress for 2cureX. In our Q3 report we expressed confidence that we were “in a very good position to fulfil our 2021 objectives in Q4”. We can now proudly say that all these objectives were achieved.

In Q4 2021 we expanded our commercial reach, with the signature of three new distribution agreements covering four new countries, added one new test (IndiTreat® Start) to our portfolio, enrolled the first hospital for our IGNITE program, and received the first commercial order in the history of 2cureX. This unprecedented series of events laid the ground for an ambitious 2022, where we expect to see IndiTreat® tests being routinely used to personalize cancer treatment of patients across Europe.

INDITREAT® NOW PROMOTED IN 14 COUNTRIES

Building up the distribution network in Europe has been one of our top priorities in 2021. Having access to the different healthcare systems in every country, promoting IndiTreat® and the concept of drug sensitivity testing in hundreds of hospitals, building the relationships with thousands of oncologists and pathologists, can only be achieved with strong local sales and support infrastructures, and that's the role of our commercial partners.

In Q4, 2021 we signed three new distribution agreements with leading In Vitro Diagnostics companies, covering four new countries: Labormed (Slovenia), Omnigen (Turkey) and Diamedica (Latvia and Lithuania). This was quickly followed by two additional agreements in the first week of January with the companies Perlan (Poland) and Promedica (Czech and Slovakia).

All in all, IndiTreat® is now being promoted in 14 different countries (up from six countries back in August). The number of new colorectal cancer cases in these countries exceeded 150,000 in 2020, so we are already addressing a very significant market potential. Our goal is to end 2022 with presence in twenty countries.

PORTFOLIO EXPANSION AND NEW INDITREAT® IMAGE

In December 2021, we announced the launch of the second IndiTreat® test. Named IndiTreat® mCRC Start, it is a test to help oncologists decide which of the available chemothera-

py combinations (known as FOLFOX, FOLFIRI and FOLFOXIRI) is better suited for a specific patient as first line treatment.

The new test also marked a new naming policy. While in the past we were referring to the tests by the treatment lines they were supporting, the new naming better reflects the intention in terms of clinical utility. Thus, the first test in the market, previously referred to as IndiTreat® mCRC 3L is now called IndiTreat® mCRC Extend. The newly launched test was previously referred to as IndiTreat® mCRC 1L and is now named IndiTreat® mCRC Start.

A third test, IndiTreat® mCRC Explore, will be launched in Q1 2022. It is intended to identify off-label treatments that can be useful for patients who have already received two or more treatment lines, therefore opening new options for oncologists to consider.

Together with the new naming, a new IndiTreat® image was launched in Q4 2021, including new logo, colors and visual elements. This new image has already been implemented in all presentations and printed materials. The new IndiTreat® website with updated contents and design will be unveiled in Q1 2022.



THE IGNITE PROGRAM WILL ACCELERATE THE USE OF INDITREAT

IGNITE stands for “Inducing Growth through a Network of IndiTreat Evaluations” and is a program we designed in 2021 to accelerate the uptake of IndiTreat® in hospitals across Europe. The participating hospitals get a limited number of patients tested with IndiTreat® at no cost, in exchange for sharing their results at conferences and scientific events. The aim is to facilitate the introduction of the new technology and create a critical mass of users as quickly as possible.

The program is being offered by 2cureX distributors in the different countries as soon as their sales teams are trained. In December we announced the signature of the first IGNITE agreement, with University Hospital Fundación Jiménez Díaz, one of the most prestigious hospitals in Spain, which is part of Quirónsalud, a private hospital group with 54 hospitals and more than 8,000 beds.

GENERATING A STABLE CASH FLOW IN 2022

In 2022 we expect to see IndiTreat® being used routinely in hospitals across Europe to design individual treatment plans for patients with cancer. We will continue to expand our

geographic coverage, signing distribution agreements to reach at least 20 countries in Europe. We will work with our distributors to introduce IndiTreat® in at least 30 hospitals and we will launch, as mentioned above, at least one more IndiTreat® test. In the back end, we keep working in improving our internal operations, and will scale up our lab facilities in Copenhagen to manage the expected incoming patient samples.

The repeated use of IndiTreat® in hospitals will during 2022 generate a stable cash flow that will mark the end of the transition period we initiated in 2021 from being a research organization to a full-fledged In Vitro Diagnostics company, and the beginning of the journey to become the global leader in oncology drug sensitivity testing.

We look forward to sharing more success stories throughout 2022 and thank our committed employees, our partners, and our loyal shareholders for the trust you have shown.

Fernando Andreu, CEO

February 24, 2022

2CUREX IN BRIEF

The key product of 2cureX is the IndiTreat® test portfolio, which allows the physician to identify the most efficient medical treatment for a particular cancer patient.

For more details see 2cureX's website at www.2curex.com



FOURTEEN COUNTRIES AND GROWING

The IndiTreat® distribution network has grown from six countries in August 2021 to fourteen countries at the beginning of 2022.

After signing up Werfen (Spain) in September, Labormed (Slovenia), Omnigen (Turkey) and Diamedica (Latvia and Lithuania) followed in Q4 2021. In the first week of January 2022 two new agreements with the companies Perlan (Poland) and Promedica (Czech and Slovakia) completed the current map.

All new distributors are In Vitro Diagnostics (IVD) companies well established in their markets, with a portfolio of products that is complementary to IndiTreat®, and extensive coverage of our target customers through sales and customer support networks.

Our Business Development has been working around the clock to get this new network up to speed, even with continuous disruptions generated by covid-associated restrictions.

DISTRIBUTOR SETUP

The signature of a new distribution agreement is followed by a number of activities, large and small, to get the distributor fully operational.


Typically, 2cureX needs to be included as a supplier in the Quality Management System of the distributor, the IndiTreat® products and services have to be added to their procurement- and logistics systems, sample collection sets are then shipped from 2cureX to the distributor warehouses, and IndiTreat® training and promotional materials need to be translated in local languages.

Then the distributor’s sales and customer support teams are trained, including technical and medical training elements, but also commercial strategy. Only after that, these teams are ready to start contacting the oncologists and pathologists in their assigned hospitals to explain the product and offer the IGNITE program. This whole process can take several weeks, depending on the complexity of the distributor.

At the moment of writing this report, all distributors have been trained by our Business Development team and are fully operational in their respective countries.

CONTINUED GROWTH IN 2022

The coverage of our current distribution network reaches approximately 35% of the European population, 235 M people, with around 150,000 new colorectal cancer cases every year and in 2022 we will continue the expansion.



ACHIEVING OUR TARGET OF THREE TESTS IN THE MARKET IN 2022

In line with our strategy of developing a full portfolio of IndiTreat® tests for colorectal cancer, we launched in December 2021, the new **IndiTreat® mCRC Start**. This is a test to help oncologists decide which of the available chemotherapy combinations – known as FOLFOX, FOLFIRI and FOLFOXIRI – is better suited for a specific patient as first line treatment.

Soon, we will be launching our third test, **IndiTreat® mCRC Explore**. This test provides information to the oncologist about the sensitivity of the patient's tumor to five different drugs and drug combinations. IndiTreat® Explore is to be used in the design of therapy regimens for patients with metastatic colorectal cancer facing their third line of treatment.

With these additions, 2cureX's IndiTreat® portfolio is made of three tests (IndiTreat® mCRC Start, IndiTreat® mCRC Extend and IndiTreat® mCRC Explore) covering all treatment steps in metastatic colorectal cancer.

INDITREAT® mCRC START

CRC patients with metastases not suited for primary surgery are offered first line systemic therapy. The chemotherapy options are typically two combinations of two drugs – FOLFOX or FOLFIRI – or, in very selected patients a combination of three drugs – FOLFOXIRI – or the monotherapy fluorouracil.

Most patients are treated with either FOLFOX or FOLFIRI in first line and when the disease progresses, the other treatment is used as second line.

The unique value of the IndiTreat® mCRC Start test is that it provides information about the sensitivity of the patient's tumor to each of these treatments. This is of major importance because getting the right therapy in first line increases the patient's chances of achieving significantly longer Progression-Free and Overall Survival.

INDITREAT® mCRC EXPLORE

When a patient shows disease progression after having received second line of treatment, one treatment option is to "re-challenge" the tumor with oxaliplatin or irinotecan-based regimens used in first line.

Another option is treatment with drugs recommended as third line in international guidelines. These are the multi-targeted kinase inhibitor regorafenib or an oral agent that combines trifluridine and tipiracil. All these drugs are covered in our IndiTreat® mCRC Extend test.

A third option is to explore if the patient's tumor is sensitive to other drugs that are approved for different indications but have shown in clinical studies to be effective in colorectal cancer as well. This is known as "off-label" use of the drugs and is accepted by the different healthcare systems under certain conditions.

IndiTreat® mCRC Explore tests sensitivity to three such regimens – mitomycin C plus fluorouracil, gemcitabine plus fluorouracil and temozolomide plus irinotecan – to give the oncologist and the patient a wider range of options in third line and beyond.

IndiTreat® mCRC Explore is complementary to IndiTreat® mCRC Extend in the sense that Extend focuses on drugs included in colorectal cancer guidelines, while Explore looks for options among drugs that are approved for other cancer indications.

A PORTFOLIO SUPPORTING PATIENTS AT DIFFERENT MOMENTS

Approximately 500,000 people are diagnosed with colorectal cancer every year in Europe. Almost 250,000 people die every year for this cause, making it the second most common cause of cancer death in both men and women.

Around 25% of patients, 125,000, show metastasis at the time of diagnosis, meaning they are classified as Stage IV. Additionally, 125,000 patients transition every year from Stage III – no distant metastasis – to Stage IV. All those patients start first line of treatment, meaning they could benefit from guidance with IndiTreat® mCRC Start.

Some 90,000 patients every year see their disease progress after having received two lines of treatment. These are the patients that, while considering their third line treatment options, could benefit from IndiTreat® mCRC Extend or IndiTreat® mCRC Explore guidance.

FOCUS ON GASTROINTESTINAL (GI) CANCER

In most countries, clinical oncologists are increasingly specialized by cancer entity. Thus, we find oncologists treating breast cancer patients, others treating gynecological cancers, others treating gastrointestinal (GI) cancers.

GI cancers includes colorectal, esophagogastric, gastric, pancreatic and hepatocellular carcinoma (HCC). Approximately one quarter of all cancers diagnosed are GI cancers. As a portfolio strategy, we decided in 2021 to develop and launch IndiTreat® tests focusing on the needs of GI oncologists. Narrowing our target to this group our commercial strategies are more effective, as there are clear synergies in the promotion of the different tests when they are addressing the same customer segment.

NEXT STEPS

With the upcoming launch of IndiTreat® mCRC Explore we will have achieved our target of having three tests in the market in 2022. Obviously, our efforts don't stop here, and we are looking at other potential indications to support therapy decision making in patients with colorectal cancer Stage III.

Still within GI, our research in pancreatic cancer is also progressing as planned. We will be informing our shareholders and interested parties throughout the year on the relevant milestones in this project.



FINANCIAL PERFORMANCE IN Q4 2021

Numbers within parentheses refer to the corresponding period in the preceding year. For additional information about 2cureX's financial position and development, please refer to the Company's website (www.2cureX.com).

NET SALES AND OPERATING INCOME

Net sales during 2021 amounted 0 KSEK (0 KSEK) and during the fourth quarter of 2021 net sales amounted to 0 KSEK (0 KSEK). Other operating income during 2021 amounted to 7,391 KSEK (15,391 KSEK) and during the fourth quarter Other operating income amounted to 2,541 KSEK (5,212 KSEK).

FINANCIAL DEVELOPMENT

The result for 2021 amounted to -18,137 KSEK (-7,320) and during the fourth quarter of 2021 the result amounted to -5,410 KSEK (-2,274 KSEK). The result for the period has been impacted by the increasing efforts to build the market awareness of our IndiTreat® technology, and commercial efforts to market IndiTreat®.

A part of the clinical operations was funded by an EU grant named MicroCaT, recognized as Other operating income in the income statement.

LIQUIDITY

The Group's cash and cash equivalents amounted to 72,942 KSEK (62,048 KSEK) as of December 31, 2021. Cash flow in 2021 amounted to 14,092 KSEK (25,513 KSEK) and during the fourth quarter of 2021 cash flow amounted to 442 KSEK (-4,140 KSEK). Cash flow from operating activities during 2021 amounted to -18,426 KSEK (-11,694 KSEK) and during the fourth quarter of 2021, cash flow from operating activities amounted to -626 KSEK (-4,206 KSEK).

The monthly burn rate amount to approximately SEK 2.3 million, which is in line with expectations.

SOLIDITY

The Group's equity ratio as of December 31, 2021 amounted to 93 % (93 %).

THE SHARE

There is one class of shares in 2cureX AB (publ). The Company's share is listed on Nasdaq First North Growth Market under the ticker "2CUREX". As of December 31, 2021, the

number of shares amounted to 17,475,716 (14,856,600). The average number of shares during the fourth quarter of 2021 amounted to 17,475,716 (14,852,683).

EMPLOYEE STOCK OPTIONS

The Annual General Meeting on 28 May 2018 resolved to establish a Series 2018/2020 and a Series 2018/2021 warrant program for the Group's employees and key personnel. The employee warrants, totalling 360 000 warrants, carry the right to subscribe for newly issued shares in 2cureX AB in the period 28 May 2020 to 28 September 2020 and in the period 1 April 2021 to 28 September 2021, respectively. The warrant programs have been recalculated concerning exercise price and the number of shares each warrant entitles to subscribe for. The recalculation is due to the rights issue performed in 2019.

Each subscription warrant entitles the holder to subscribe for 1.06 share (before recalculation 1.0 share), at a subscription price of 8.40 SEK (before recalculation 8.86 SEK) per share. Upon full exercise of the issued warrants, the share capital would increase by 38 160 SEK (before recalculation 36 000 SEK). The employee warrants will be subject to the usual conversion terms in connection with new share issues etc.

The extraordinary general meeting on 5 November 2020 resolved to establish a warrant program for 3 new board members. The warrant program totalling 120 000 warrants carry the right to subscribe for newly issued shares in 2cureX AB in the period from 1 October 2023 up to an including 31 December 2023. Each subscription warrant entitles the holder to subscribe for 1 share, at a subscription price of 16,56 SEK.

The Annual General Meeting on 27 May 2021 resolved to establish a Series 2021/24 warrant program for the Group's CEO. The warrants, totaling 700 000 warrants, carry the right to subscribe for newly issued shares in 2cureX AB in the period 1 April 2022 to 30 June 2022 (233 333 warrants), in the period 1 April 2023 to 30 June 2023 (233 333 warrants) and in the period 1 April 2024 to 30 June 2024 (233 334 warrants), respectively.

POLICIES FOR THE PREPARATION OF THE INTERIM FINANCIAL REPORT

2cureX AB applies the Swedish Annual Accounts Act as well as the Swedish Accounting Standards Board BFNAR 2012:1 annual report and consolidated (K3) in the preparation of its financial reports.

AUDITORS' REVIEW

This interim report has not been reviewed by the Company's auditors.

FINANCIAL CALENDAR

The Company prepares and publishes a financial report at the end of each quarter. Upcoming reports are planned to be released as follows:

- **Annual report 2021** **3/5-2022**
- **Interim Report Q1, 2022** **24/5-2022**
- **Annual General Meeting** **24/5-2022**
- **Interim Report Q2, 2022** **25/8-2022**
- **Interim Report Q3, 2022** **24/11-2022**
- **Interim Report Q4, 2022** **23/2-2023**



DELIVERY OF INTERIM REPORT

Landskrona, February 24, 2022 2cureX AB

BOARD OF DIRECTORS

Povl-André Bendz
Chairman of the Board

Jørgen Drejer
Member of the Board

Camilla Huse Bondesson
Member of the Board

Michael Lutz
Member of the Board

Ole Thastrup
Member of the Board and CSO

Nils Brünner
Member of the Board

Fernando Andreu
CEO

CERTIFIED ADVISER

Svensk Kapitalmarknadsgranskning AB

Phone: +46 70 755 95 51

E-mail: ca@skmg.se

FINANCIAL OVERVIEW



FINANCIAL OVERVIEW

THE GROUP

SUMMARY OF INCOME STATEMENT –THE GROUP (KSEK)	Q4 2021 1/10-31/12	Q4 2020 1/10-31/12	Q1-Q4 2021 1/1-31/12	Q1-Q4 2020 1/1-31/12
Operating income				
Net sales	0	0	0	0
Other operating income	2 541	5 212	7 391	15 391
Total operating income	2 541	5 212	7 391	15 391
Operating expenses				
Other external expenses	-4 416	-3 484	-11 863	-10 063
Personnel costs	-5 365	-3 085	-17 976	-12 360
Depreciation of tangible fixed assets	-78	-105	-353	-386
Total operating expenses	-9 859	-6 674	-30 192	-22 809
Operating profit	-7 318	-1 462	-22 801	-7 418
Financial posts	41	-1 356	322	-1 173
Profit before tax	-7 276	-2 818	-22 479	-8 591
Tax ¹⁾	1 067	544	3 542	1 271
The result of the period	-6 210	-2 274	-18 937	-7 320
Earnings per share (SEK)	-0,36	-0,15	-1,15	-0,54
Average number of shares	17 475 716	14 853 683	16 418 767	13 604 775
No. of shares at the end of the period	17 475 716	14 856 600	17 475 716	14 856 600

¹⁾ This post refers to tax relief in subsidiaries regarding R&D work.

**SUMMARY OF BALANCE SHEET
– THE GROUP (KSEK)**

Q1-Q4 2021 **Q1-Q4 2020**
1/1-31/12 1/1-31/12

Assets		
Fixed assets		
Tangible fixed assets	691	996
Total fixed assets	691	996
Current assets		
Receivables	5 527	3 471
Cash and bank balances	72 942	58 577
Total current assets	78 469	62 048
Total assets	79 160	63 044
Equity and liabilities		
Equity		
Share capital	1 748	1 485
Ongoing share issue	13	0
Other contributed capital	107 663	75 388
Other equity	-16 143	-10 690
The result of the period	-18 937	-7 320
Total equity	74 344	58 863
Current liabilities		
Short-term liabilities ²⁾	4 816	4 181
Total short-term liabilities	4 816	4 181
Total equity and liabilities	79 160	63 044

**SUMMARY OF CASH FLOW
– THE GROUP (KSEK)**

Q4 2021 **Q4 2020** **Q1-Q4 2021** **Q1-Q4 2020**
1/10-31/12 1/10-31/12 1/1-31/12 1/1-31/12

Cash flow from operating activities	-626	-4 206	-18 426	-11 694
Cash flow from investment activities	0	-24	-32	-403
Cash flow from financing activities	1 068	90	32 550	37 610
Cash flow for the period	442	-4 140	14 092	25 513
Cash and cash equivalents at the beginning of the period	72 498	63 977	58 577	33 720
Exchange rate difference in cash and cash equivalents	2	-1 260	273	-656
Cash and cash equivalents at the end of the period	72 942	58 577	72 942	58 577

CHANGE OF EQUITY – THE GROUP

1/1-2020 – 31/12-2020

(KSEK)	Share capital	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2020)	1 242	38 023	-3 256	-7 933	28 076
Outline of previous year's results			-7 933	7 933	0
Rights issue	244	39 873			40 117
Issue costs		-2 508			-2 508
Allocation of staff warrants			399		399
Translation difference			100		100
The result of the period				-7 320	-7 320
At the end of the period (31/12-2020)	1 486	75 388	-10 690	-7 320	58 864

1/1-2021 – 31/12-2021

(KSEK)	Share capital	Ongoing share issue	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2021)	1 486	0	75 388	-10 690	-7 320	58 864
Outline of previous year's results				-7 320	7 320	0
Issue of shares	262	13	34 243			34 518
Issue cost			-1 968			-1 968
Allocation of staff warrants				2 027		2 027
Translation difference				-160		-160
The result of the period					-18 937	-18 937
At the end of the period	1 748	13	107 663	-16 143	-18 937	74 344

FINANCIAL OVERVIEW

PARENT COMPANY

SUMMARY OF INCOME STATEMENT – PARENT COMPANY (KSEK)	Q4 2021 1/10-31/12	Q4 2020 1/10-31/12	Q1-Q4 2021 1/1-31/12	Q1-Q4 2020 1/1-31/12
Operating income				
Net sales	0	0	0	0
Total operating income	0	0	0	0
Operating expenses				
Other external expenses	-595	-974	-1 898	-2 493
Staff costs	-1 067	-0	-1 639	-0
Total operating expenses	-1 662	-974	-3 537	-2 493
Operating profit	-1 662	-974	-3 537	-2 493
Financial posts	-119	310	-272	465
Profit before tax	-1 781	-664	-3 809	-2 028
Tax	0	0	0	0
The result of the period	-1 781	-664	-3 809	-2 028

SUMMARY OF BALANCE SHEET – PARENT COMPANY (KSEK)	Q1-Q4 2021 1/1-31/12	Q1-Q4 2020 1/1-31/12
Assets		
Fixed assets		
Financial assets	29 275	28 318
Total fixed assets	29 275	28 318
Current assets		
Receivables	552	305
Cash and bank balances	67 176	37 961
Total current assets	67 728	38 266
Total assets	97 003	66 584
Equity and liabilities		
Equity		
Share capital	1 748	1 485
Ongoing share issue	13	0
Other contributed capital	111 863	79 588
Other equity	-13 165	-13 164
The result of the period	-3 809	-2 028
Total equity	96 650	65 881
Current liabilities		
Current liabilities	353	703
Total short-term liabilities	353	703
Total equity and liabilities	97 003	66 584

SUMMARY OF CASH FLOW – PARENT COMPANY (KSEK)	Q4 2021 1/10-31/12	Q4 2020 1/10-31/12	Q1-Q4 2021 1/1-31/12	Q1-Q4 2020 1/1-31/12
Cash flow from operating activities	-410	-926	-3 335	-2 183
Cash flow from investment activities	0	0	0	0
Cash flow from financing activities	1 068	89	32 550	37 610
Cash flow for the period	658	-837	29 215	35 427
Cash and cash equivalents at the beginning of the period	66 518	38 798	37 961	2 534
Cash and cash equivalents at the end of the period	67 176	37 961	67 176	37 961

CHANGE OF EQUITY – PARENT COMPANY

1/1-2020 – 31/12-2020

(KSEK)	Share capital	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2020)	1 242	42 223	-11 646	-1 917	29 902
Outline of previous year's results			-1 917	1 917	0
Rights issue	244	39 873			40 117
Issue costs		-2 508			-2 508
Allocation of staff warrants			399		399
The result of the period				-2 028	-2 028
At the end of the period (31/12-2020)	1 486	79 588	-13 164	-2 028	65 882

1/1-2021 – 31/12-2021

(KSEK)	Share capital	Ongoing share issue	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2021)	1 486	0	79 588	-13 164	-2 028	65 882
Outline of previous year's results				-2 028	2 028	0
Issue of shares	262	13	34 243			34 518
Issue costs			-1 968			-1 968
Allocation of staff warrants				2 027		2 027
The result of the period					-3 809	-3 809
At the end of the period (31/12-2021)	1 748	13	111 863	-13 165	-3 809	96 650

THE POWER
OF PRECISION.
FOR EVERY
ONCOLOGIST.
TODAY.



2CUREX AB (publ)

Corporate registration number: **559128-0077**

2CUREX A/S

Fruebjergvej 3 / DK-2100 Copenhagen / Denmark
Phone: +45 2211 5399 / E-mail: info@2curex.com
